Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year

Affiliation auteurs!!!! Error affiliation !!!!
TitreCognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year
Type de publicationJournal Article
Year of Publication2017
AuteursCohen M, Brochet B, Clavelou P, Le Page E, Vermersch P, Tourbah A, Moreau T, Joly H, Sakarovitch C, Lebrun C, Grp QStudy
JournalJOURNAL OF THE NEUROLOGICAL SCIENCES
Volume382
Pagination73-78
Date PublishedNOV 15
Type of ArticleArticle
ISSN0022-510X
Mots-clésBeta interferon, CIS, Cognition, health-related quality of life, mri, treatment response
Résumé

{Cognition and health-related quality of life (HRQoL) are early involved in multiple sclerosis (MS). The aim of QUALICIS study was to monitor cognition and HRQoL prospectively in a cohort of clinically isolated syndrome (CIS) patients starting a treatment with subcutaneous beta-1b interferon as a first disease modifying treatment (DMT), and to assess their correlation with the clinical outcome 6 years later. Relapse history, EDSS and yearly standardized brain MRI data were also collected. 37 patients were included. Cognition and HRQoL remained stable over treatment period. At baseline, we found that SDMT was moderately correlated to T2 lesion load (r = -0.47
DOI10.1016/j.jns.2017.09.030